Residual viability is a predictor of the perfusion enhancement obtained with the cell therapy of chronic myocardial infarction: a pilot multimodal imaging study.

Date publication

août 2012

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle

Tous les auteurs :
Maureira P, Tran N, Djaballah W, Angioi M, Bensoussan D, Didot N, Fay R, Sadoul N, Villemot JP, Marie PY

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/22785499

Résumé

PURPOSE: Up to now, there has been limited investigation into cell therapy in the chronic phase of severe myocardial infarction (MI), and many questions remain concerning the contribution of the engrafted cells and especially their impact on the reperfusion of MI areas, when assessed by objective quantitative imaging techniques. This randomized pilot SPECT, PET, and MRI study was aimed at assessing the effects of bone marrow mononuclear cells (BMNCs) when implanted in areas of severe and chronic MI. MATERIALS AND METHODS: Fourteen patients, who were referred for coronary artery bypass grafting (CABG) and in whom a screening MIBI-SPECT revealed severely damaged myocardium ( +9%) in only 3 cell therapy patients, whose MI areas before therapy had a higher FDG uptake [59% (9%) vs 38% (8%), P = 0.03] and a lower transmural extent at MRI [40% (6%) vs 73% (18%), P = 0.03] when compared with the other cell therapy patients. CONCLUSIONS: Perfusion enhancement, obtained with BMNCs in areas of chronic MI, might require an intermediate level of viability documented with FDG-PET and MRI and that totally necrotic MI seems refractory to this cell therapy technique.

Référence

Clin Nucl Med. 2012 Aug;37(8):738-42